EnBio Holdings, Inc. (6092) AI Stock Analysis

• Market Cap: ¥5.34B
• Dividend Yield: 1.38%
• Average Volume (3M): 11.16K
• Price to Earnings (P/E): 11.7
• Beta (1Y): 0.66
• Revenue Growth: 11.41%
• EPS Growth: -37.29%
• Country: JP
• Employees: 104
• Sector: Industrials
• Sector Strength: 84
• Industry: Specialty Business Services
• EPS (TTM): -13.91
• Shares Outstanding: 8,175,200
• 10 Day Avg. Volume: 10,470
• 30 Day Avg. Volume: 11,156
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥747.00
• Price Target Upside: 13.70% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 68 Neutral
• Price Target: ¥747.00 ▲(13.70% Upside)

The overall stock score for EnBio Holdings, Inc. is driven primarily by strong financial performance, particularly in revenue growth and operational efficiency. Technical analysis suggests positive market momentum, though caution is warranted due to overbought signals. The valuation is attractive, offering a reasonable P/E ratio and a modest dividend yield.

EnBio Holdings, Inc. Business Overview & Revenue Model

Company Description

EnBio Holdings, Inc. (6092) is a Japanese company specializing in environmental biotechnology solutions. It operates in sectors such as environmental conservation, waste management, and pollution control. The company is focused on developing and providing innovative technologies and services that address environmental challenges, including soil remediation, water purification, and waste treatment. EnBio Holdings is committed to sustainability and the creation of a cleaner environment through its advanced biotechnological applications.

How the Company Makes Money

EnBio Holdings, Inc. generates revenue through the sale and implementation of its environmental biotechnology solutions. The company's primary revenue streams include fees from consulting services, sales of proprietary bioremediation products, and contracts for large-scale environmental projects. EnBio Holdings partners with government agencies, industrial clients, and private enterprises to provide tailored solutions that help meet regulatory requirements and sustainability goals. Additionally, the company may receive revenue from licensing agreements for its patented technologies and products.

EnBio Holdings, Inc. Financial Statement Overview

Summary

EnBio Holdings, Inc. shows strong revenue growth and operational efficiency with healthy EBIT and EBITDA margins. However, the decline in net income and challenges in cash flow management, particularly negative free cash flow, could pose risks.

Income Statement

EnBio Holdings, Inc. shows a robust performance with strong revenue growth of 11.44% from 2024 to 2025, indicating positive business momentum. The gross profit margin stands at 24.87% and the net profit margin at 4.24% for 2025, which are moderate but consistent over the years. However, the decline in net income from 2024 to 2025 suggests some pressure on profitability. The EBIT and EBITDA margins are healthy at 7.95% and 12.58%, respectively, reflecting efficient operational management.

Balance Sheet

The balance sheet of EnBio Holdings, Inc. reveals a solid equity base with a debt-to-equity ratio of 1.10, indicating a balanced capital structure. The return on equity (ROE) is relatively low at 4.95% for 2025, showing room for improvement in generating returns for shareholders. The equity ratio is 43.14%, suggesting a stable financial position with a reasonable level of leverage.

Cash Flow

The cash flow statement indicates challenges with free cash flow, which turned negative in 2025, driven by high capital expenditures. The operating cash flow to net income ratio is low at 0.05, highlighting potential inefficiencies in cash generation relative to net income. However, the company has maintained positive operating cash flow, which is a positive indicator of ongoing operational health.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	10.67B	9.58B	8.12B	8.99B	6.84B
Gross Profit	2.65B	2.48B	2.76B	2.43B	1.89B
EBITDA	1.34B	1.62B	1.76B	1.57B	981.00M
Net Income	452.69M	708.76M	812.06M	654.05M	304.06M
Balance Sheet
Total Assets	21.20B	19.31B	17.35B	16.37B	15.70B
Cash, Cash Equivalents and Short-Term Investments	3.29B	3.60B	2.83B	2.37B	2.02B
Total Debt	10.10B	8.62B	8.90B	8.58B	9.04B
Total Liabilities	11.96B	10.72B	10.49B	10.40B	10.38B
Stockholders Equity	9.14B	8.49B	6.79B	5.89B	5.29B
Cash Flow
Free Cash Flow	-1.44B	584.36M	824.13M	1.25B	-1.43B
Operating Cash Flow	21.92M	1.66B	1.99B	2.41B	297.16M
Investing Cash Flow	-1.60B	-1.58B	-1.77B	-1.48B	-2.16B
Financing Cash Flow	1.27B	638.92M	240.73M	-534.92M	928.54M

EnBio Holdings, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 657.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6092, the sentiment is Positive. The current price of 657 is above the 20-day moving average (MA) of 644.95, above the 50-day MA of 633.86, and above the 200-day MA of 596.38, indicating a bullish trend. The MACD of 7.07 indicates Negative momentum. The RSI at 71.18 is Negative, neither overbought nor oversold. The STOCH value of 91.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6092.

EnBio Holdings, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7883	74 Outperform	¥5.44B	13.90		2.28%	-1.10%	26.19%
7850	72 Outperform	¥2.61B	5.69		2.24%	1.84%	75.79%
Sector *	71 Outperform	¥260.34B	14.71	8.48%	2.82%	6.35%	12.05%
7812	70 Outperform	¥5.26B	5.18		4.48%	-0.27%	36.59%
6092	68 Neutral	¥5.34B	11.72		1.38%	11.41%	-37.29%
3948	66 Neutral	¥6.93B	65.78		3.33%	-15.74%	-80.43%
7916	60 Neutral	¥4.36B	61.77		3.50%	0.38%	24.47%

EnBio Holdings, Inc. Corporate Events

EnBio Holdings Reports Fiscal Year 2025 Financial Results with Revenue Growth Amid Profit Decline

EnBio Holdings, Inc. reported its consolidated financial results for the fiscal year ended March 31, 2025, showing an increase in net sales by 11.4% to ¥10,668 million. However, the company experienced a decline in ordinary profit and profit attributable to owners of the parent by 34.2% and 36.1%, respectively. The financial results reflect challenges in maintaining profitability despite revenue growth. The inclusion of two new companies, DEFNE ENERGY INVESTMENT INDUSTRY TRADE LIMITED and EnBio C West, G.K., in its consolidation scope indicates strategic expansion efforts. The forecast for the next fiscal year predicts further growth in net sales and profits, suggesting a positive outlook for the company’s future performance.